Skip to content

IORT Versus CCRT for Pancreatic Cancer

Intraoperative Radiotherapy (IORT) Versus Concurrent Chemoradiotherapy (CCRT) for Pancreatic Cancer

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02981641
Acronym
IVCPC
Enrollment
100
Registered
2016-12-05
Start date
2015-12-31
Completion date
2018-12-31
Last updated
2016-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Cancer Stage IV

Keywords

Pancreatic cancer, Intraoperative radiotherapy (IORT), Concurrent Chemoradiotherapy (CCRT)

Brief summary

The purpose of this study is to find the better radiation therapy between intraoperative radiotherapy (IORT) and concurrent chemoradiotherapy (CCRT).

Detailed description

The trial is funded by National High-tech R&D Program (863 Program). The trial is prepared to be registered on the clinicaltrail.gov. Quality assurance plan: Every participant is enrolled or excluded by two practiced investigators. And two investigators participated in all steps of the trail, including the record of the data, and the investigators will compare the data. If the data is consistent, the investigators would record the data; if not, the data would be checked and decided by the two investigators. All the steps and data are site monitored and audited by the workers of research and financial department of The First Affiliated Hospital of China Medical University Data check: The investigators compare data entered into the registry against predefined rules for range or consistency with other data fields in the registry. Source data verification to assess the accuracy, completeness, or representativeness of registry data by comparing the data to external data sources, including medical records and electronic case report forms. Data dictionary that contains detailed descriptions of each variable used by the registry, including the source of the variable, coding information, and normal ranges if relevant. Standard Operating Procedures to address registry operations and analysis activities, such as participants recruitment, data collection, data management, data analysis, reporting for adverse events, and change management. All registry operations would be done according to specific steps, and by two practiced investigators. Sample size assessment to specify the number of participants or participant years necessary to demonstrate an effect. According to the formula to differ advantages and disadvantages, the investigators need at least 100 participants to take part in the trail. The investigators can recruit about 120 participants every year according to previous experiences, so the investigators should recruit at least for one years. Plan for missing data: The investigators would collect as much data as possible, and the investigators exclude the participants who cannot cooperate on recruitment. And the investigators manage situations according to statistical principles where variables are reported as missing, unavailable, non-reported, uninterpretable, or considered missing because of data inconsistency or out-of-range results. Statistical analysis plan: Kaplan-Meier method would be used to analyze the difference of survival time between the two groups, and the local control rate of the two groups would be compared by chi square test. Statistical analyses would be performed by using IBM SPSS Statistics(version 20; IBM, Chicago, USA). The level of significance is defined as P \< 0.05.

Interventions

Total dose: 18\ 22 Gy; Single dose: 18\ 22 Gy; Frequency: 1

DRUGSequential chemotherapy

Sequential chemotherapy

RADIATIONThree dimensional conformal radiation therapy (3D-CRT)

Total dose: 60 Gy; Single dose: 2 Gy; Frequency: 30

DRUGConcurrent chemotherapy

Gemcitabine (GEM), 800 mg/m2 weekly on Day 1-21, Q28d; or S-1 orally, 400 mg/d, bid on Day 1-21, Q28d

Sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosed as locally advanced pancreatic cancer. * Cannot be treated by surgical resection.

Exclusion criteria

* Treated by chemotherapy or radiotherapy before. * With distant organ metastasis. * Cannot tolerate surgery (Intraoperative radiotherapy)

Design outcomes

Primary

MeasureTime frameDescription
Overal survival3 yearsOS

Secondary

MeasureTime frameDescription
Disease-specific survival3 yearsDSS
Progression-free survival3 yearsPFS
Local control rate3 yearsLCR

Countries

China

Contacts

Primary ContactJianwei Zhang, Ph.D.
panchutong@163.com+8613581841816
Backup ContactShuisheng Zhang, M.D.
thelifeofwater@126.com+8618001302322

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026